MalDA, Accelerating Malaria Drug Discovery

Tuo Yang, Sabine Ottilie, Eva S. Istvan, Karla P. Godinez-Macias, Amanda K. Lukens, Beatriz Baragaña, Brice Campo, Chris Walpole, Jacquin C. Niles, Kelly Chibale, Koen J. Dechering, Manuel Llinás, Marcus C. S. Lee, Nobutaka Kato, Susan Wyllie, Case W. McNamara, Francisco Javier Gamo, Jeremy Burrows, David A. Fidock, Daniel E. GoldbergIan H. Gilbert, Dyann F. Wirth, Elizabeth A. Winzeler,

Research output: Contribution to journalReview articlepeer-review

1 Citation (Scopus)

Abstract

The Malaria Drug Accelerator (MalDA) is a consortium of 15 leading scientific laboratories. The aim of MalDA is to improve and accelerate the early antimalarial drug discovery process by identifying new, essential, druggable targets. In addition, it seeks to produce early lead inhibitors that may be advanced into drug candidates suitable for preclinical development and subsequent clinical testing in humans. By sharing resources, including expertise, knowledge, materials, and reagents, the consortium strives to eliminate the structural barriers often encountered in the drug discovery process. Here we discuss the mission of the consortium and its scientific achievements, including the identification of new chemically and biologically validated targets, as well as future scientific directions.

Original languageEnglish
Number of pages15
JournalTrends in Parasitology
DOIs
Publication statusE-pub ahead of print - 26 Feb 2021

Keywords

  • malaria
  • MalDA
  • Plasmodium falciparum
  • target-based drug discovery
  • drug resistance

Fingerprint Dive into the research topics of 'MalDA, Accelerating Malaria Drug Discovery'. Together they form a unique fingerprint.

Cite this